WO2006109175A3 - Solid dosage form of an antidiabetic drug - Google Patents

Solid dosage form of an antidiabetic drug Download PDF

Info

Publication number
WO2006109175A3
WO2006109175A3 PCT/IB2006/001007 IB2006001007W WO2006109175A3 WO 2006109175 A3 WO2006109175 A3 WO 2006109175A3 IB 2006001007 W IB2006001007 W IB 2006001007W WO 2006109175 A3 WO2006109175 A3 WO 2006109175A3
Authority
WO
WIPO (PCT)
Prior art keywords
solid dosage
antidiabetic drug
dosage form
dosage forms
relates
Prior art date
Application number
PCT/IB2006/001007
Other languages
French (fr)
Other versions
WO2006109175A2 (en
Inventor
Venkata Rama Rao Kamala
Srinivasa Rao Shaik
Ashish Gogia
Sivakumaran Meenakshisunderam
Original Assignee
Aurobindo Pharma Ltd
Venkata Rama Rao Kamala
Srinivasa Rao Shaik
Ashish Gogia
Sivakumaran Meenakshisunderam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurobindo Pharma Ltd, Venkata Rama Rao Kamala, Srinivasa Rao Shaik, Ashish Gogia, Sivakumaran Meenakshisunderam filed Critical Aurobindo Pharma Ltd
Publication of WO2006109175A2 publication Critical patent/WO2006109175A2/en
Publication of WO2006109175A3 publication Critical patent/WO2006109175A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

The present invention relates to solid dosage forms of an antidiabetic drug glyburide. More particularly, the present invention relates to solid dosage forms of antidiabetic drug glyburide with specific particle size and specific surface area.
PCT/IB2006/001007 2005-04-11 2006-04-10 Solid dosage form of an antidiabetic drug WO2006109175A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN403CH2005 2005-04-11
IN403/CHE/2005 2005-04-11

Publications (2)

Publication Number Publication Date
WO2006109175A2 WO2006109175A2 (en) 2006-10-19
WO2006109175A3 true WO2006109175A3 (en) 2007-02-08

Family

ID=37087398

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/001007 WO2006109175A2 (en) 2005-04-11 2006-04-10 Solid dosage form of an antidiabetic drug

Country Status (1)

Country Link
WO (1) WO2006109175A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
EP3763419A1 (en) 2011-01-07 2021-01-13 Anji Pharma (US) LLC Chemosensory receptor ligand-based therapies
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
NZ626578A (en) 2012-01-06 2016-11-25 Elcelyx Therapeutics Inc Compositions and methods for treating metabolic disorders
JP2015503582A (en) 2012-01-06 2015-02-02 エルセリクス セラピューティクス インコーポレイテッド Biguanide compositions and methods of treating metabolic disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3979520A (en) * 1973-09-26 1976-09-07 Boehringer Mannheim G.M.B.H. Preparation of rapidly resorbable glibenclamide
US4060634A (en) * 1973-09-26 1977-11-29 Boehringer Mannheim G.M.B.H. Rapidly resorbable glibenclamide
WO2001051463A1 (en) * 2000-01-14 2001-07-19 Bristol-Myers Squibb Company Glyburide composition
US20050260273A1 (en) * 2001-06-07 2005-11-24 Chinea Vanessa I Applicatin of a bioactive agent in a solvent composition to produce a target particle morphology

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3979520A (en) * 1973-09-26 1976-09-07 Boehringer Mannheim G.M.B.H. Preparation of rapidly resorbable glibenclamide
US4060634A (en) * 1973-09-26 1977-11-29 Boehringer Mannheim G.M.B.H. Rapidly resorbable glibenclamide
WO2001051463A1 (en) * 2000-01-14 2001-07-19 Bristol-Myers Squibb Company Glyburide composition
US6830760B2 (en) * 2000-01-14 2004-12-14 Bristol-Myers Squibb Company Glyburide composition
US20050260273A1 (en) * 2001-06-07 2005-11-24 Chinea Vanessa I Applicatin of a bioactive agent in a solvent composition to produce a target particle morphology

Also Published As

Publication number Publication date
WO2006109175A2 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
WO2006109175A3 (en) Solid dosage form of an antidiabetic drug
WO2006091529A3 (en) A solid pharmaceutical dosage formulation
IL195488A (en) Compounds, pharmaceutical compositions comprising the same and uses thereof
RS60205B1 (en) Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
WO2006097537A3 (en) Acylated glp-1 compounds
AP2344A (en) N-Thio-anthranilamid compounds and their use as pesticides.
IL225206A (en) Polycyclic carbamoylpyridone derivative, pharmaceutical composition comprising the same and use thereof
GEP20115245B (en) Solid preparation
WO2006127941A3 (en) Amorphous cinacalcet hydrochloride and preparation thereof
IL198289A (en) Substituted dihydropyrazolones, processes for their preparation, medicaments comprising them and their use for the preparation of such medicaments
IL205705A (en) Anti-influenza antibodies, compositions comprising the same and uses thereof
EP2016635A4 (en) Co-crushed mixture of an active material and of a conductive material, preparation methods and uses thereof
IL184288A0 (en) 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactones and pharmaceutical preparations comprising the same
ZA200801988B (en) 4-oxy-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
ZA200900673B (en) 18-methyl-19-nor-androst-4-en-17, 17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-one) and pharmaceutical preparations containing the same
EP1948138A4 (en) Segmented pharmaceutical dosage forms
WO2008073863A3 (en) Preparation and utility of substituted allylamines
USD529382S1 (en) Actuator cap
WO2007141743A3 (en) A tablet dosage form comprising cetirizine and pseudoephedrine
WO2007009989A3 (en) COMPOSITION CONTAINING A SIO2-NANOPARTICLE LIPOSOMAL DISPERSION AND AN ß-1,3-LINKED GLUCAN-ETHER DERIVATIVE
WO2006085228A3 (en) 9a-carbamoyl-y-aminopropyl and 9a-thiocarbamoyl-y-aminopropyl-azalides with antimalarial activity
IL186851A0 (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
WO2006095173A3 (en) Medical uses of 39-desmethoxyrapamycin and analogues thereof
USD527411S1 (en) Type font
ZA200706706B (en) Hydroxyphenol derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06744563

Country of ref document: EP

Kind code of ref document: A2